Is change in hemostatic markers after recombinant tissue-type plasminogen activator associated with the chance of recanalization?
From a practical point of view, the measurement of these hemostatic markers is probably not useful for predicting recanalization.
Our results provided the experimental evidence that linagliptin treatment initiated after the appearance of hypertension and cardiac hypertrophy protected against cardiovascular injury induced by salt-sensitive hypertension, independently of blood pressure and blood glucose. These beneficial effects of linagliptin seem to be attributed to the reduction of oxidative stress and ACE.